Annovis Bio Inc. (NYSE: ANVS) reported significant third quarter 2025 progress, led by full activation of all 84 sites in its pivotal Phase 3 Alzheimer’s study (NCT06709014) and steady enrollment across the U.S. The company also announced promising biomarker data from its Phase 2/3 Alzheimer’s trial showing strong reductions in inflammation and neurodegeneration, underscoring buntanetap’s disease-modifying potential.
Recent achievements include transferring all patents to the new crystal form of buntanetap with IP protection through 2046, publishing supportive pharmacokinetic data, and appointing veteran finance executive Mark Guerin as CFO. “Every element is now aligned as we move toward our data readouts—the final step before an NDA submission,” said Maria Maccecchini, Ph.D., president and CEO.
The company is a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer’s and Parkinson’s. Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as AD and PD. The company is committed to developing innovative therapies that improve patient outcomes and quality of life.
For more information, visit www.annovisbio.com and follow on LinkedIn, YouTube, and X. The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS.
